Xigen Overview
- Year Founded
-
2002
- Status
-
Out of Business
- Employees
-
6
- Latest Deal Type
-
Out of Business
Xigen General Information
Description
Developer of innovative therapeutic peptides designed to be used against inflammation. The company's peptides have metabolic stability, and specificity and are selectively delivered to intracellular targets through proprietary carrier molecules, enabling physicians to treat a broad range of diseases.
Contact Information
Website
www.xigenpharma.comCorporate Office
- Route de la corniche 4
- 1066 Epalinges
- Switzerland
Corporate Office
- Route de la corniche 4
- 1066 Epalinges
- Switzerland
Xigen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 01-Feb-2021 | Completed | Out of Business | |||
| 5. Later Stage VC (Series B) | 16-Nov-2009 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Private | 01-Jan-2008 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 06-Sep-2005 | Completed | Generating Revenue | |||
| 2. Angel (individual) | 19-Jan-2004 | Completed | Generating Revenue | |||
| 1. University Spin-Out | 01-Jan-2002 | Completed | Startup |
Xigen Patents
Xigen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2013091670-A1 | Novel jnk inhibitor molecules for treatment of various diseases | Inactive | 21-Dec-2011 | ||
| WO-2012048721-A1 | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases | Inactive | 14-Oct-2010 | ||
| WO-2012048893-A1 | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases | Inactive | 14-Oct-2010 | ||
| WO-2011160653-A1 | Novel jnk inhibitor molecules | Inactive | 21-Jun-2010 | ||
| WO-2011160827-A2 | Novel jnk inhibitor molecules | Inactive | 21-Jun-2010 | C07K7/08 |
Xigen Signals
Xigen FAQs
-
When was Xigen founded?
Xigen was founded in 2002.
-
Where is Xigen headquartered?
Xigen is headquartered in Epalinges, Switzerland.
-
What is the size of Xigen?
Xigen has 6 total employees.
-
What industry is Xigen in?
Xigen’s primary industry is Drug Discovery.
-
Is Xigen a private or public company?
Xigen is a Private company.
-
What is Xigen’s current revenue?
The current revenue for Xigen is .
-
How much funding has Xigen raised over time?
Xigen has raised $40.7M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process